Section Arrow
NGNE.NASDAQ
- Neurogene
Quotes are at least 15-min delayed:2026/01/05 03:36 EST
Regular Hours
Last
 20.16
-0.44 (-2.14%)
Day High 
21.1743 
Prev. Close
20.6 
1-M High
23.0006 
Volume 
102.94K 
Bid
--
Ask
--
Day Low
19.62 
Open
20.66 
1-M Low
19.03 
Market Cap 
328.46M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.28 
20-SMA 20.37 
50-SMA 24.07 
52-W High 37.265899 
52-W Low 6.875 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.10/-4.34
Enterprise Value
338.61M
Balance Sheet
Book Value Per Share
17.14
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
925.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.